In the current study, the main findings related to hypoglycaemia frequency and glucodynamics were that the risk of hypoglycaemia was comparable for icodec vs glargine U100 following double and triple doses, the duration of decline in PG towards clinically significant hypoglycaemia (PG3.0 mmol/l) was also comparable for both insulin products, and full recovery from hypoglycaemia was achieved within 30 min during constant i.v. glucose infusion at 5.5 mg kg−1 min−1 for both icodec and glargine U100. This evidence concerns the gene INS and Hypoglycemia.